Lowering blood pressure is one of the few lifestyle-adjacent levers with a proven payoff on hard disease. Randomized drug trials show that dropping the number cuts heart attacks and strokes, and, on newer evidence, dementia as well. The benefit reaches people who have never had heart disease, and it does not disappear as pressure falls into the normal range; the observational “J-curve” that once seemed to warn against going low turns out to be a study artifact.
That payoff comes with a catch worth stating up front. Blood pressure is a surrogate, so the decision that matters is a person’s absolute cardiovascular risk, not whether they hit a particular BP target. And the proven transmission — the step from a lower number to fewer events — has been demonstrated for drug-lowered pressure. Lifestyle levers each move the number a few points, but whether that drop reaches events is mostly an assumption; one diet route, a potassium salt substitute, is the exception that actually measured it. Two framings follow from this. Drugs are the realistic comparator, not the enemy of lifestyle change. And sodium policy stays genuinely contested for someone with normal pressure eating a moderate amount — it is settled only for the hypertensive heavy-salt user.
Moving the number moves the disease — proven for drugs, on two outcomes
Start with the question every lever answers to: does moving the number actually move the disease? For drug-lowered blood pressure, the answer is a firm yes. The largest randomized evidence base finds that «a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values» (Blood Pressure Lowering Treatment Trialists Collaboration, 2021). Primary prevention is included in that estimate, and no treatment J-curve appears — the relative benefit holds down to the lowest blood-pressure strata, with no subgroup running the wrong way.
One landmark trial operationalizes the finding. SPRINT randomized high-risk hypertensives to an intensive versus a standard systolic target and stopped early: the intensive arm cut the primary composite (hazard ratio 0.75) and, more unusually, «All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73…)» (SPRINT Research Group, 2015). The gain came at a real cost — higher rates of hypotension, syncope, electrolyte abnormalities and acute kidney injury (SPRINT Research Group, 2015). So a lower target buys hard events in a high-risk person, but the target itself is a net-effect judgment, not lower-is-always-better.
A second patient-important outcome now sits alongside cardiovascular events. Pooling five double-blind placebo-controlled antihypertensive trials, Peters 2022 reports «an adjusted odds ratio 0.87 (95% confidence interval: 0.75, 0.99) in favour of antihypertensive treatment reducing risk of incident dementia» (Peters et al., 2022). Randomization again erases the observational U: achieved blood pressure showed «a linear relationship between lower risk of dementia and lower BP, down to at least 100 mmHg systolic and 70 mmHg diastolic» (Peters et al., 2022). The protective-looking lower arm of the registry curves fails the interventional check here, exactly as it did for cardiovascular events -> The U-Shaped Association Artifact.
Two cautions travel with the dementia result, and both are binding. First, this is a NEW outcome, not independent confirmation of the cardiovascular-events evidence: Peters’ five trials sit inside the same meta-analytic base and share author lineage (the George Institute group), so they do not corroborate the blood-pressure-lowering mechanism a second time — it is a new-endpoint extension, not an independent replication. Second, the transmission is proven for DRUG-lowered blood pressure; whether a lifestyle- or sodium-lowered drop reaches dementia is the same assumption already flagged for events.
preDIVA sharpens where the dementia benefit lives. In unselected over-70s, six years of nurse-led blood-pressure-lowering vascular care did not reduce dementia overall, but it removed a standing worry — the authors report that «such an intervention is safe, which is in accordance with findings from the recent SPRINT trial» in this age group (van Charante et al., 2016). Any benefit concentrated where hypertension was genuinely untreated — among those adherent to the intervention with untreated hypertension at baseline, a post-hoc effect-modification hypothesis. The lever pays where the deficit is real, not in an already-managed population.
Decide on absolute risk, not on a BP number
A proven relative effect is not a mandate to lower everyone’s number. The ~10%-per-5-mmHg reduction is a property of the intervention; what it buys a given person is that same relative reduction applied to their own baseline risk — absolute risk difference = relative risk reduction x baseline risk (Schünemann et al., n.d.). So the identical drop is a small absolute gain at low risk and a large one at high risk. A modest relative effect can be decisive for someone at high baseline risk and immaterial for someone at low risk, with no disagreement about the evidence -> Baseline Risk and the Relative-Absolute Split.
This is where a stratum baseline does the work. Rather than treating to a fixed BP threshold, combine the relative effect with a stratum-specific 10-year cardiovascular risk — the kind SCORE2 supplies and against which ESC sets its treatment bands (European Society of Cardiology, 2021) -> SCORE2 Baseline Risk and the ESC Treatment Thresholds. BPLTTC’s own authors legislate the same rule: physicians should «emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself» (Blood Pressure Lowering Treatment Trialists Collaboration, 2021). The exact BP reading matters less than the overall risk it sits inside.
None of this refutes the ceiling on lifestyle levers — it refines it. Blood-pressure lowering’s relative benefit is proven where lifestyle weight-loss and GLP-1 cardiovascular benefit are not, but its absolute benefit still scales with baseline risk, which is the ceiling’s own mechanism. A constant ~10% per 5 mmHg is worth pulling hard for a hypertensive at high cardiovascular risk and barely worth measuring for a low-risk normotensive.
The lifestyle levers, and how much each moves the number
With that decision rule in hand, here is how much each lifestyle lever actually moves the number. Two things govern how to read the list. First, a millimetre of mercury is not a millimetre of prevented disease: every figure below is a change in the surrogate (blood pressure), and whether that drop reaches heart attacks and strokes has been tested separately for each lever. Flag each one’s status: MEASURED where a randomized trial watched the hard events fall (only the potassium salt substitute clears this bar), MODELLED where the events were projected through a risk model rather than counted (alcohol), and ASSUMED for every other route — the BP drop is real, its transmission to events borrowed from the drug evidence.
Second, a big number is not the same as a good one. Rank the levers by effect times certainty, not by the headline mmHg. The two largest point estimates on the page — mindfulness at -9.12 and beetroot at -4.4 — carry the weakest evidence (unblinded, hugely heterogeneous, or measured over hours to days on a surrogate), so a smaller-but-solid mover like sodium reduction outranks them for someone deciding where to spend effort. And several of these levers overlap: do not add their mmHg together (below).
Cut sodium — the certain few mmHg
Reducing salt intake lowers systolic BP by about -4.18 mmHg (95% CI -5.18 to -3.18) across everyone and -5.39 mmHg (-6.62 to -4.15) in people who are already hypertensive (He et al., 2013) — a modest reduction sustained four or more weeks, with HIGH certainty on the BP effect itself. The full appraisal (the very-low certainty on hard outcomes, the contested low-intake arm, the salt-sensitivity gradient) lives on Sodium Intake and Blood Pressure; here it is the best-evidenced dietary BP mover, framed as a substitution: swap the salt-delivering foods (processed meats, bread, restaurant meals) for lower-sodium versions. Transmission: ASSUMED — the BP fall is high-certainty, but that it reaches events rests on the drug evidence, not a sodium-reduction outcome trial.
More potassium — real, but only if your BP is already up
Raising potassium intake lowers systolic BP by -3.49 mmHg (95% CI 1.82 to 5.15) on average — but that average hides a clean split. In people with hypertension the fall is -5.32 mmHg (3.43 to 7.20); in people with normal BP it is +0.09 mmHg (-0.77 to 0.95), essentially zero, not merely smaller (Aburto et al., 2013). So eat more potassium is advice for a hypertensive, not a normotensive — the mirror image of sodium, which still moves a normal BP. The electrolyte physiology (the sodium-to-potassium ratio, the CKD contraindication) belongs on Sodium Intake and Blood Pressure and Potassium Intake and Blood Pressure, not here.
The substitution that carries potassium also carries the page’s one MEASURED transmission. In SSaSS, swapping regular salt for a 75%-sodium / 25%-potassium substitute cut stroke (RR 0.86), major cardiovascular events (RR 0.87) and death (RR 0.88) over 4.7 years in high-risk rural Chinese adults (Neal et al., 2021). That is the only lifestyle route on this page where a trial actually watched the events fall — but the substitute cuts sodium and raises potassium at once, so the benefit belongs to the combined switch, not to potassium alone, and it rides on an extreme baseline risk (72% had a prior stroke).
Adopt the DASH pattern
Eating the DASH pattern — more fruit, vegetables, low-fat dairy and wholegrains, less red meat, sweets and saturated fat — instead of a typical Western diet lowers systolic BP by -5.2 mmHg (95% CI -7.0 to -3.4) and diastolic by -2.6 mmHg (-3.5 to -1.7), with a small LDL co-benefit and no effect on glucose or HDL (Siervo et al., 2014). The fall is larger in people who start with higher BP or BMI, and the exposure is the whole pattern — the trials cannot pin the effect on any one component, and Siervo’s own meta-regression shows it is not the incidental sodium difference doing the work. Transmission: ASSUMED (surrogate trials, 2-24 weeks; the often-quoted 13% lower CVD risk is a modelled Framingham projection, not counted events).
Do not double-count DASH with sodium or potassium. The pattern already embeds both minerals, so its -5.2 mmHg overlaps their separate figures — you cannot sum them as independent levers. They do stack when deliberately combined (adding salt restriction on top of DASH buys further reduction, as the DASH-Sodium factorial showed), but that is stacking two applied interventions, not attributing DASH’s own effect to its salt content.
Structured exercise — for a hypertensive, in the range of a drug
For a hypertensive person, structured exercise (endurance or dynamic resistance) is a credible-magnitude BP lever. In the stratum matched to the drug trials (baseline SBP >=140), exercise lowered systolic BP by -8.96 mmHg (95% CrI -10.27 to -7.64), and the network meta-analysis found no difference between it and first-line medication (Naci et al., 2018). The catch is the population: unmatched, drugs looked far better only because the drug trials enrolled sicker people — the confound was the finding. Transmission: ASSUMED (Naci measured no events). The full exercise-versus-drug hedge — indirect network evidence, sparser and higher-bias exercise trials — belongs to the next section; here the point is the magnitude, at hypertensive baselines only. At a normotensive baseline the exercise effect shrinks to about -4.84 mmHg.
Drink less — if you drink more than two a day
Cutting alcohol lowers BP, but the effect is confined to heavier drinkers. Below about two drinks a day there is no significant change; above it the fall is dose-dependent, from -1.18 mmHg at three drinks a day to -5.50 mmHg (95% CI -6.70 to -4.30) at six or more, with an overall -3.13 mmHg (-3.93 to -2.32), GRADE-high (Roerecke et al., 2017). So this lever only exists for someone drinking heavily; the two-drinks figure marks where the BP signal begins, not a target to drink up to. The substitution is simply fewer drinks. Full dose-response on mortality and vascular disease sits on Alcohol and Mortality and Vascular Disease.
Transmission: MODELLED. Roerecke did not count cardiovascular events — it projected them through a comparative-risk model (over 7,000 UK hospitalisations, 678 CV deaths), assuming the BP drop persists and transmits with no lag. That is one step better than pure assumption but a step short of SSaSS’s counted events.
Beetroot and dietary nitrate — a big estimate on thin evidence
Inorganic nitrate (beetroot juice or leafy greens) lowers systolic BP by about -4.4 mmHg (95% CI -5.9 to -2.8) versus placebo, with diastolic BP not moving (-1.1 mmHg, CI crosses zero); a larger nitrate dose predicts a larger fall, and roughly 8 mmol a day (one big beetroot shot or a large serving of leafy greens) is what reaches a >=2 mmHg drop (Siervo et al., 2013).
Hold this LOW-to-moderate, and do not let the tidy point estimate fool you (the T4 rule in action): the trials ran hours to fifteen days, in mostly young healthy men, on resting BP — and the effect was not confirmed on 24-hour ambulatory monitoring, precisely in the older, higher-risk people who would benefit. Transmission: ASSUMED (surrogate only; the bridge to events is a modelled projection, and the observed drop is below the 5 mmHg that projection assumes).
Lose weight — proven for other things, not for BP-to-events
Weight loss is a genuine lever for glycaemia, diabetes remission and fatty liver — but its blood-pressure-to-events case is the weakest here, and the honest verdict is a caution. In Look AHEAD, the largest and longest lifestyle-weight-loss trial, an intensive programme improved nearly every risk factor yet did not reduce cardiovascular events (HR 0.95, 95% CI 0.83 to 1.09), and the 54-trial meta-analysis confirms the null on CV events (RR 0.93) (Look AHEAD Research Group, 2013). Transmission: NULL on events even when the weight came off — the surrogates moved (BP, HbA1c, inflammation), the events did not follow. The trial’s BP-drop magnitude itself is thinly reported here; weight loss earns its place on this page as a caution, not a BP number. Its real payoffs are on Does Weight Loss Reduce Cardiovascular Events.
Stress-management (MBSR) — the largest estimate, the least warrant
An 8-week mindfulness-based programme (MBSR) posts the biggest point estimate on the page — systolic BP -9.12 mmHg (95% CI -12.18 to -6.05) — and it is the clearest case for the T4 rule, because that number is the least trustworthy here. Four features cut the same way: the trials could not be blinded (patients knew their arm), heterogeneity is extreme (I2=92%), most participants were medicated, and in unmedicated patients the effect was a null (+0.53 mmHg) (Chen et al., 2024). So the honest read is LOW certainty, and the likely mechanism is improved medication adherence rather than a direct stress-to-BP drop. Transmission: ASSUMED (no events, follow-up <=3 months). Treat MBSR as an adherence aid for an already-medicated patient who struggles with compliance — not as a standalone antihypertensive. Detail on Stress Management and Cardiometabolic Health.
Dietary magnesium — a marker, not a separate lever
Higher dietary magnesium tracks lower stroke and type-2-diabetes risk in cohort studies, but as a blood-pressure lever it is weak and probably not independent. The magnesium-rich foods — wholegrains, leafy greens, nuts, beans — are the same whole-food, plant-rich pattern behind DASH and potassium, and the authors cannot rule out that magnesium is simply a marker of that diet rather than the active ingredient (Fang et al., 2016). The base is observational, with no hard-outcome trial. Transmission: ASSUMED, and shakier than the rest. So eat magnesium-rich whole foods is fine advice, but it is already carried by the DASH recommendation above — magnesium adds no separate, separately-actionable BP lever. Detail on Dietary Magnesium and Cardiometabolic Outcomes.
For a hypertensive, exercise matches a drug on the number — but the drug’s payoff is the proven one
The honest comparator for any lifestyle BP lever is not nothing; it is a first-line antihypertensive. The best evidence placing the two on one axis is a network meta-analysis of 391 randomized trials — 197 of exercise, 194 of drugs — that never ran a head-to-head. Compared against control, drugs looked far stronger (about -8.80 vs -4.84 mmHg). But the two arms were measured in different people: the drug trials enrolled hypertensives at a mean systolic pressure over 150 mmHg, the exercise trials people around 132, mostly normotensive. A blood-pressure drop scales with where you start, so those are not the same quantity. Restrict exercise to the hypertensive trials and its effect nearly doubles, erasing the drug’s lead: «We did not observe a difference between the SBP-lowering effects of medications and exercise (0.18, 95% CrI −1.35 to 1.68)». (Naci et al., 2018)
Read that equivalence with two hedges intact. The authors grant it only «Assuming equally reliable estimates, the SBP-lowering effect of exercise among hypertensive populations appears similar to that of commonly used antihypertensive medications» (Naci et al., 2018) — and the estimates are not equally reliable. The matched exercise stratum rests on 56 trials against the drugs’ 194, and most exercise trials carry a high risk of performance and detection bias because you cannot blind a person to whether they are exercising. That weakness is structural, not a fixable oversight. So the finding is not exercise equals drugs; it is that at hypertensive baselines a structured exercise programme is a credible-magnitude lever, on thinner and lower-grade evidence.
What breaks the tie is transmission. The drug arm inherits the proven outcome step — pharmacological BP-lowering cuts major cardiovascular events by about 10% per 5 mmHg (Blood Pressure Lowering Treatment Trialists Collaboration, 2021) — while the systolic number in the exercise trials is a surrogate: nobody measured events, and whether an exercise-induced drop transmits at the drug’s rate is the same assumption flagged for every lifestyle route. Against that, exercise carries structural leverage a pill does not, acting on the driver rather than managing the marker, plus off-target benefits a BP-only comparison ignores. Neither dominates on every axis, so the choice — drug, exercise, or both — stays the person’s. This is a comparison of levers, not a guide to which agent, dose, or target; that is a prescriber’s call and sits outside this appraisal.
Cut sodium if you are hypertensive and eat a lot of salt; below that, the evidence runs out
Sodium carries a policy fight the other levers do not, and it is a genuine one: the two readings give opposite answers for roughly 90% of people. One pole (WHO and the He/MacGregor lineage) reads sodium-to-BP as a high-certainty, near-linear relation and urges everyone toward under 2 g/day. The other (the PURE cohorts) sees a J-shaped curve on hard outcomes and would target only hypertensives who also eat a lot of salt. At that overlap — a hypertensive with high intake — both poles agree: reduce.
They diverge for the normotensive at moderate intake, roughly 3-6 g/day, and there the honest state is insufficient evidence, not a settled recommendation either way. Symmetric standards decide it. The population-wide pole cannot claim monotone benefit at hard outcomes as proven — that leg is transferred from a surrogate, rated very low on the endpoints that matter. And PURE’s protective-looking low arm is not causal on its face: against a 4-5 g/day reference category, both high sodium excretion (>7 g/day: HR 1.23, 95% CI 1.11-1.37) and low excretion (<3 g/day: HR 1.34, 95% CI 1.23-1.47) carried increased cardiovascular risk (Mente et al., 2016).
The two poles also measure different things — a randomized reduction versus a single spot-urine estimate of habitual intake — over different ranges, and the disputed low arm sits where the trials have almost no data. Unequal measurement error at the intake extremes can bend a flat relation into a U with no confounder at all, so PURE’s lower arm goes through the artifact diagnostics before it is believed as causal.
One later, larger source touches the fight without ending it. BPLTTC finds a 5 mmHg drop cuts events «irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values» (Blood Pressure Lowering Treatment Trialists Collaboration, 2021), which weakens PURE’s premise that BP-lowering only helps above 140. But that does not settle the sodium tension: PURE’s low arm is a direct sodium-to-outcome signal, a separate claim from whether lowering BP below 140 helps. The full sodium evidence lives on Sodium Intake and Blood Pressure; it is not re-derived here.
For whom, and how low to go
The unsettled low arm where the sodium evidence ran out is one instance of the last question. The same relative effect lands differently on different people, so the last decision is not how much does BP-lowering work but for whom is it worth doing, and to what target.
Baseline cardiovascular risk is the master stratifier
A fixed ~10% fewer major CV events per 5 mmHg is a small absolute gain for someone at low risk and a large one for someone at high risk (Blood Pressure Lowering Treatment Trialists Collaboration, 2021). That is route (a): the relative effect holds across strata, and the absolute benefit rides on the baseline. So the person’s 10-year CVD risk — read from SCORE2/SCORE2-OP and placed against the ESC bands, which move with age — decides who to treat, not the BP reading itself (SCORE2 Baseline Risk and the ESC Treatment Thresholds, Baseline Risk and the Relative-Absolute Split). Treat to risk, not to a threshold on the number.
Salt-sensitivity: the sodium lever pays where pressure is already high
Who benefits from cutting salt is not everyone equally. Sodium reduction lowers systolic pressure about three times more in a hypertensive person (roughly -5.4 mmHg) than in a normotensive one (roughly -2.4 mmHg) (He et al., 2013); the sharper reading is that the true modifier is continuous baseline SBP, of which the hypertensive/normotensive split is a coarse summary. The full appraisal, including the Na:K joint-lever question and salt-sensitivity mechanics, lives on Sodium Intake and Blood Pressure — carried here as a pointer, not re-derived.
Age, kidney function, and a contraindication that fires
Two strata bound the recommendation at its edges.
- Age. The ESC treatment thresholds rise with age, and above 70 the lipid-lowering recommendation softens to may be considered (SCORE2 Baseline Risk and the ESC Treatment Thresholds). For BP itself, preDIVA removes the old worry that lowering pressure in the over-70s harms cognition: it found the intervention safe (van Charante et al., 2016). Any dementia benefit concentrated among those adherent to the intervention with untreated hypertension at baseline (HR 0.54, 0.32-0.92), not in an already-managed population (van Charante et al., 2016).
- Chronic kidney disease. A potassium-based salt substitute — the one diet route with measured event benefit — is contraindicated where potassium excretion is impaired, because of hyperkalaemia risk. Details and the route-(c) boundary are on Sodium Intake and Blood Pressure; do not read the salt-substitute result across to a CKD patient.
How low to go is a net-effect judgement, not “lower is better”
SPRINT is the trial that tested an aggressive target head-on: a systolic goal below 120 versus below 140 in high-risk, non-diabetic hypertensives. Intensive control won on hard outcomes — primary composite «hazard ratio … 0.75; 95% CI 0.64 to 0.89» and all-cause mortality «hazard ratio, 0.73; 95% CI 0.60 to 0.90», with an NNT of 61 over 3.26 years (SPRINT Research Group, 2015).
But the same trial priced the target. Serious «hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not … injurious falls» rose in the intensive arm (SPRINT Research Group, 2015). A lower target buys real events at a real adverse-event cost, and that trade is largest where baseline risk is highest — so how low to go is a net-effect judgement weighed per person, not a rule that less is always better.
The diastolic J-curve is an observational artifact, not a reason to stop short
Registries show a J-shape — risk lowest around 130/75, apparently higher below — which for years read as a warning against lowering pressure far, especially the diastolic number. Run that lower arm through the artifact diagnostics before believing it (The U-Shaped Association Artifact). The randomized check erases it: BPLTTC finds benefit down below 120 mmHg systolic with no rising hazard in any low-BP stratum (Blood Pressure Lowering Treatment Trialists Collaboration, 2021), and Peters reports «no evidence of a U-shaped re- lation of the effect at any age» for dementia, monotone down to at least 100/70 (Peters et al., 2022). So the observational J is confounding and reverse causation (frail, sick people run low pressure), not a treatment effect. The genuine limit on how low to go is SPRINT’s adverse-event side above — not the J-curve.
The levers, ranked — and what is still unknown
Pulling the decision together: a handful of moves lower blood pressure, they are not equal, and the honest ranking weighs how much each moves the number against how sure we are it reaches disease and how realistically a person can sustain it.
Where to act, in order
- A first-line antihypertensive drug, for a hypertensive person. The one lever with directly proven transmission to hard events and to dementia, and the only one whose benefit is shown in primary prevention (Blood Pressure Lowering Treatment Trialists Collaboration, 2021). It is the realistic comparator every lifestyle route is measured against, not the enemy of lifestyle.
- Structured exercise. At hypertensive baselines it lowers systolic pressure about as much as a first-line drug in the matched stratum, and it carries large off-target benefits a BP-only comparison ignores (Blood Pressure Lowering and Cardiovascular Events). Its event payoff, though, is assumed, not measured.
- Cut sodium (if hypertensive / high-intake), adopt a DASH pattern. Solid surrogate effects on pressure; the step from a BP drop to fewer events is mostly assumed. The lone measured exception is a potassium salt substitute (SSaSS), and even that moves sodium and potassium together (Sodium Intake and Blood Pressure).
- Drink less — but only above two drinks a day. Below that the BP effect is flat; the lever exists for the heavier drinker (Blood Pressure Lowering and Cardiovascular Events).
- Weight loss, dietary nitrate, stress-management, magnesium. Real levers, but each is thin, short-duration, or low-certainty; a large point estimate on weak evidence does not outrank a smaller certain one.
Through all of it, one decision rule holds: act on absolute cardiovascular risk, not on hitting a number.
What we still do not know
Four gaps are genuine, and none is closed by an obvious source sitting unread.
- No direct exercise-versus-drug trial exists. The equivalence is inferred across a network of separate trials, never a head-to-head randomization.
- Sodium’s low arm is not adjudicated. No Mendelian-randomization instrument and no large trial of sodium level (rather than reduction) has separated a genuine low-intake harm from measurement artifact.
- Lifestyle-to-events transmission is mostly assumed. Only the SSaSS salt substitute measured hard outcomes; for every other diet or behaviour route, that a BP drop reaches disease is an inference, not a finding.
- The weight-loss BP-magnitude leg is thin. Lifestyle weight loss was null on hard events even when achieved (Look AHEAD), and the BP-drop magnitude for weight loss is weakly characterized (Does Weight Loss Reduce Cardiovascular Events).
Evidence box
Question ’For an adult with elevated blood pressure or drifting toward it: what is the effect of each modifiable exposure (diet, weight, activity, alcohol, specific nutrients, stress, and drug therapy as the realistic alternative) on blood pressure and on downstream patient-important cardiovascular outcomes, how large and how certain is each, does a given blood-pressure change transmit to those outcomes, and how do the levers rank for a stratum?‘ Evidence included 19 sources — 10 gold, 8 high Overall certainty High (see Rating Certainty of Evidence) Source-selection note All sources are gold or high tier. Last updated 2026-09-04 · Independently reviewed: No · Full edit history